ONWARD Medical Secures Over EUR 40 Million in Capital Increase

ONWARD Medical N.V. successfully raised EUR 40.6M through an expedited bookbuild offering. This funding includes a significant investment of EUR 25.0M from EQT Life Sciences and support from other long-term investors. The newly issued shares, priced at EUR 3.00 each, are set to begin trading on April 20, 2026, on Euronext exchanges in Brussels, Amsterdam, and Paris.

The funds aim to support ONWARD’s development and commercialization efforts, particularly for the ARC-IM® System, which addresses blood pressure instability in people with spinal cord injuries. ONWARD anticipates that the proceeds will extend its financial capabilities into the first quarter of 2028.

CEO Dave Marver highlighted the importance of this transaction, emphasizing the rapid market adoption of the ARC-EX® System and the promising future of the ARC-IM® platform currently undergoing clinical evaluation.